5.32
price down icon4.49%   -0.25
 
loading
前日終値:
$5.57
開ける:
$5.57
24時間の取引高:
1.33M
Relative Volume:
0.55
時価総額:
$409.71M
収益:
$409.00K
当期純損益:
$-101.35M
株価収益率:
-3.2439
EPS:
-1.64
ネットキャッシュフロー:
$-71.49M
1週間 パフォーマンス:
-8.43%
1か月 パフォーマンス:
-17.13%
6か月 パフォーマンス:
-17.77%
1年 パフォーマンス:
-47.74%
1日の値動き範囲:
Value
$5.30
$5.57
1週間の範囲:
Value
$5.30
$6.16
52週間の値動き範囲:
Value
$5.14
$11.16

Altimmune Inc Stock (ALT) Company Profile

Name
名前
Altimmune Inc
Name
セクター
Healthcare (1166)
Name
電話
(240) 654-1450
Name
住所
910 CLOPPER ROAD, GAITHERSBURG, MD
Name
職員
59
Name
Twitter
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
ALT's Discussions on Twitter

ALT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ALT
Altimmune Inc
5.32 409.71M 409.00K -101.35M -71.49M -1.64
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Altimmune Inc Stock (ALT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-28 開始されました William Blair Mkt Perform
2025-01-08 開始されました Stifel Buy
2024-11-12 開始されました UBS Buy
2024-04-29 ダウングレード Guggenheim Buy → Neutral
2024-01-24 開始されました Goldman Neutral
2023-03-22 ダウングレード Goldman Buy → Neutral
2022-12-01 開始されました Goldman Buy
2021-12-29 再開されました Jefferies Buy
2021-06-02 開始されました H.C. Wainwright Buy
2021-02-11 開始されました Guggenheim Buy
2020-12-14 開始されました Jefferies Buy
2020-11-12 繰り返されました B. Riley Securities Buy
2020-09-25 開始されました B. Riley FBR Buy
2020-08-14 開始されました Evercore ISI Outperform
2020-07-31 開始されました Piper Sandler Overweight
2020-07-28 開始されました JMP Securities Mkt Outperform
2020-02-24 再開されました ROTH Capital Buy
2019-07-19 開始されました ROTH Capital Buy
2017-10-09 開始されました Piper Jaffray Overweight
すべてを表示

Altimmune Inc (ALT) 最新ニュース

pulisher
Mar 22, 2025

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - Yahoo

Mar 22, 2025
pulisher
Mar 19, 2025

Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey

Mar 19, 2025
pulisher
Mar 17, 2025

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine (ALT) - Seeking Alpha

Mar 17, 2025
pulisher
Mar 17, 2025

Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Mar 17, 2025
pulisher
Mar 17, 2025

Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 16, 2025

Altimmune rises as buyout rumors follow R&D updates - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Altimmune CFO Gregory Weaver purchases $51,996 in stock By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 14, 2025

Altimmune Outlines Pemvidutide Plans In MASH And Beyond - News & Insights

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune soars amid takeover speculation - MSN

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune stock rises amid buyout and R&D news(ALT:NASDAQ) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

(ALT) Trading Advice - Stock Traders Daily

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders - Benzinga India

Mar 14, 2025
pulisher
Mar 14, 2025

Stifel maintains Buy on Altimmune stock, $18 price target - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Stifel maintains Buy on Altimmune stock, $18 price target By Investing.com - Investing.com UK

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune rises on plans to test obesity drug for alcohol use disorder, other conditions - TradingView

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune CFO Gregory Weaver purchases $51,996 in stock - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens JMP reiterates Altimmune stock with $25 target By Investing.com - Investing.com South Africa

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens JMP reiterates Altimmune stock with $25 target - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

Promising Potential of Altimmune’s Pemvidutide Drives Buy Rating Amid Expanding Indications and Strong Market Outlook - TipRanks

Mar 14, 2025
pulisher
Mar 13, 2025

Altimmune to test obesity drug for alcohol use disorder and related health conditions - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Altimmune gains on plans to test weight-loss drug for alcohol use disorder, other conditions - TradingView

Mar 13, 2025
pulisher
Mar 12, 2025

SBI Securities Co. Ltd. Acquires New Shares in Altimmune, Inc. (NASDAQ:ALT) - Defense World

Mar 12, 2025
pulisher
Mar 10, 2025

Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 09, 2025

Altimmune, Inc. to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 07, 2025

Rhumbline Advisers Has $756,000 Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

HC Wainwright Has Bearish Estimate for Altimmune Q2 Earnings - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Altimmune to Host Virtual R&D Day on March 13, 2025 - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Altimmune, Inc. Announces Virtual R&D Day Focused on Pemvidutide Development and Upcoming Trial Data - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Can Altimmune's Pemvidutide Transform Both Obesity and MASH Treatment? R&D Day to Reveal Full Potential - StockTitan

Mar 06, 2025
pulisher
Mar 06, 2025

Altimmune FY2029 EPS Forecast Decreased by HC Wainwright - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire

Mar 05, 2025
pulisher
Mar 05, 2025

Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire

Mar 05, 2025
pulisher
Mar 04, 2025

H.C. Wainwright maintains Altimmune stock Buy rating, $12 target By Investing.com - Investing.com Australia

Mar 04, 2025
pulisher
Mar 04, 2025

H.C. Wainwright maintains Altimmune stock Buy rating, $12 target - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Altimmune (NASDAQ:ALT) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire

Mar 03, 2025

Altimmune Inc (ALT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Altimmune Inc (ALT) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
WEAVER GREGORY L
Chief Financial Officer
Mar 13 '25
Buy
5.20
10,000
51,996
10,000
Garg Vipin K
President and CEO
Feb 02 '25
Option Exercise
0.00
18,950
0
363,364
Garg Vipin K
President and CEO
Feb 01 '25
Option Exercise
0.00
16,545
0
351,645
Garg Vipin K
President and CEO
Jan 30 '25
Option Exercise
0.00
26,775
0
342,696
Harris Matthew Scott
Chief Medical Officer
Feb 02 '25
Option Exercise
0.00
7,775
0
84,564
Harris Matthew Scott
Chief Medical Officer
Feb 01 '25
Option Exercise
0.00
6,166
0
78,898
Harris Matthew Scott
Chief Medical Officer
Jan 30 '25
Option Exercise
0.00
9,275
0
74,000
Roberts M Scot
Chief Scientific Officer
Feb 02 '25
Option Exercise
0.00
7,775
0
75,536
Roberts M Scot
Chief Scientific Officer
Feb 01 '25
Option Exercise
0.00
6,166
0
69,562
Roberts M Scot
Chief Scientific Officer
Jan 30 '25
Option Exercise
0.00
9,275
0
62,921
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):